About this source
- Kind
- Research
- Design
- RCT, Human clinical trial
- Population
- Human, venous stasis ulcer patients, n=73, 8 European sites (5 Italy, 3 Poland), Phase 2
- Sample size
- 73
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Phase 2 trial published as a short report. The abstract gives no adverse-event counts. Topical full-length thymosin beta-4 (RGN-137), not the TB-500 fragment. Verified from the Europe PMC abstract record. The abstract does not contain the figure of a 40% shorter healing time that appears in the TB-500 profile.
Cited in
RGN-137 venous ulcer Phase II
Thymosin beta-4 · Research finding
Preliminary
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.